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Objective: We sought to determine clinical characteristics of NF2 patients with spinal lesions
and to deﬁne when and like the spinal tumors are a major problem in the treatment of
patients with NF2.
Methods: The authors retrospectively reviewed the clinical records, neuroimaging studies,
and follow-up data of the 34 patients with neuroﬁbromatosis type 2, who were treated at our
institution between 1998 and 2014. 23 patients harbored one or multiple spinal tumors.
Results: Patients with spinal tumors had a lower age at ﬁrst symptoms of the disease, a
higher number of intracranial meningiomas and non-vestibular schwannomas. 11 patients
had one or more intramedullary tumors with MRI characteristics of spinal ependymomas.
22 patients had intradural extramedullary tumors. 7 patients presented with symptomatic
spinal tumors on admission or developed symptoms during the follow-up. Only two
intramedullary and four extramedullary tumors demonstrated growth in the mean radio-
logical follow-up period of over 6 years. It was found that symptomatic both intra- and
extramedullary tumors were associated with younger age at the onset of NF2-related
symptoms. 2 patients with intramedullary tumors and 12 patients with extramedullary
tumors underwent their tumors resection. In case of symptomatic tumors partial recovery
was observed in two patients.
Conclusion: It seems that close surveillance with MR imaging is a reasonable option for
asymptomatic spinal tumors. Nevertheless, intramedullary tumor removal in non-growing
and asymptomatic cases may be an option when ABI implantation is considered. Symp-
tomatic tumors and those of documented growth should be eligible for surgical intervention.
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Neuroﬁbromatosis type 2 is an autosomal dominant syndrome
predisposing to multiple benign tumors of the central and* Corresponding author at: Klinika Neurochirurgii, ul. Banacha 1a, 02-0
E-mail address: arkady.n@wp.pl (A. Nowak).
http://dx.doi.org/10.1016/j.pjnns.2015.11.004
0028-3843/# 2015 Polish Neurological Society. Published by Elsevier Speripheral nervous system. The hallmark of this disease is the
development of bilateral vestibular schwannomas, which
occurs in 90–95% of patients [1–3]. Spinal NF2-associated
tumors include schwannomas of spinal nerves, meningiomas
and spinal cord ependymomas. Schwannomas of the spinal97 Warszawam, Poland. Tel.: +48 606 787 433; fax: +48 225991574.
p. z o.o. All rights reserved.
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almost 90% of extramedullary spinal tumors [4,5]. Intra-
dural, extramedullary spinal meningiomas are present in
about 20% of patients [1–4]. These tumors, however, may not
be distinguished radiologically or even at the time of
surgery. Ependymomas account for more than 75% of
intramedullary spinal cord tumors associated with neuroﬁ-
bromatosis type 2 [4,6–8]. Their imaging evidence is found in
18–53% of patients but they cause clinical symptoms in
fewer than 20% [4–6,9]. Intramedullary astrocytomas of the
spinal cord and intramedullary schwannomas have been
rarely reported in NF2 [4–9]. In contrast to sporadic tumors,
the majority of NF2-related spinal tumors are asymptomatic
during observation. Although several previous reports
concerned clinical and imaging characteristics of spinal
tumors little is known about their natural history in these
patients. In this study we sought to evaluate probability of
growth of various spinal tumor subtypes, identify prognostic
factors for symptomatic cases and establish a strategy for
the management of these tumors. Moreover we aim to
assess the risk and effectiveness of surgical treatment for
this tumor types. We compare NF2 patients with spinal
tumors to those without in order to identify differences
between the two patient subgroups. We assessed clinical
characteristics, growth patterns and surgical outcome of
spinal tumors in NF2 patients with long-term clinical and
imaging follow-up.
2. Material and methods
2.1. Patient population
34 patients with neuroﬁbromatosis type 2, as deﬁned on the
basis of the modiﬁed National Institute of Health (NIH)
Consensus Panel Criteria [10], were surgically treated at our
institution between 1998 and 2014. We have retrospectively
reviewed the clinical records, neuroimaging studies, and
follow-up data of the treated patients. Among 34 patients, in
11 we did not identiﬁed any spinal tumors whereas 23
harbored one or multiple spinal tumors. Patients with
spinal tumors were divided into those with intramedullary
tumors and those with extramedullary tumors or intradural
tumors of the cauda equina. Some patients were included
in more than one subgroup because they had tumors in both
locations. Three symptomatic spinal tumors in 3 patientsTable 1 – NF2 patients' characteristics.
Characteristic 
Spinal tumor presen
Female 14 (61) 
Mean age at ﬁrst symptoms (SD) (years) 19 (10.3) 
Bilateral vestibular schwannoma 20 (87) 
Non-vestibular schwannoma 9 (39) 
Intracranial meningioma 16 (70) 
SD – standard deviation.
Values in bold indicate statistical signiﬁcance(1 meningioma in thoracic spine and 2 schwannomas in
cauda equina) were resected in their childhood at another
institution without sequel and were not included in the
surgical treatment and growth rate analysis. We included in
the natural growth study patients who harbored intra- or
extramedullary spinal tumor and were observed for at least 1
year. Resected tumors were graded according to the WHO
2000 and the WHO 2007 [11] grading scheme.
2.2. Clinical and radiological follow-up
Our treatment philosophy assumed that the optimal strategy
for each NF2 patient is to maintain good quality of life for as
long as possible with special attention to maintain hearing.
NF2 is not a one uniform illness but comprises several
subtypes of tumor of the brain, spinal cord and peripheral
nerves and as the spontaneous clinical course of the disease
varies from patient to patient it may need different treatment
strategies. The rule of conduct in every newly diagnosed case
of NF2 was the performance of the brain and entire spine MRI
diagnostics. Then all patients with spinal tumors had a clinical
examination and spinal MRI study performed at least once a
year. MRI was aimed at determining the presence of a tumor,
deﬁning its nature and in particular evaluating of any tumor
growth in subsequent studies.
2.3. Statistical analysis
Data analyses were performed using Statistica version 12.0
(StatSoft) by means of Student's t-test and contingency tables
using the Pearson Chi-square test or Chi-square test with
Yates correction. Signiﬁcance level was established at p < 0.05.
3. Results
3.1. Patient and tumor characteristics
There were 19 women and 15 men in the entire cohort of NF2
patients. Characteristics of the patients and the comparison
between NF2 patients with spinal tumors and those without
the lesions are given in Table 1. Among the 23 patients with
spinal tumors non-vestibular schwannomas were signiﬁcant-
ly more frequently observed (p < 0.05). Besides, patients with
spinal tumors had a lower age at ﬁrst symptoms of the disease
and had a higher number of intracranial meningiomas.No. of patients (%) p-Value
t 23 (67) Spinal tumor absent 11 (33)
5 (45) 0.63
23 (9) 0.28
11 (100) 0.54
0 (0) 0.045
5 (45) 0.33
Table 2 – Characteristics of patients harboring intramedullary tumors.
Case
no.
Age at
ﬁrst
symptoms
Sex Tumors
location
Multiple
tumors
Growing or
symptomatic
tumor
Cystic tumor Coexisted
extramedullary
tumors
Coexisted
intracranial
meningioma
1 28 F C1-C2
Th3
Th9-Th11
(+) (+) (+)
2 19 F C1
C6
(+) (+) (+)
3 3 F C1-C5
Th4-Th6
(+) (+) (+) (+) (+)
4 13 F C3 (+) (+)
5 36 M C1-C2
6 10 F C2-C4
C7
(+) (+) (+)
7 16 F C2-C3 (+) (+)
8 3 M C2-C5 (+) (+) (+) (+) (+)
9 27 M C4-C7 (+) (+) (+)
10 16 F C1-C5 (+) (+) (+)
11 6 F C2-C3
C6-C7
Th2-Th3
Th7-Th8
(+) (+) (+)
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11 patients had one or more intramedullary tumors with MRI
characteristics of spinal ependymomas (Table 2). Multiple
ependymomas with the MRI appearance of a ‘‘string of pearls’’
were seen in 8 (73%) patients. The cervical spine or cervicome-
dullary junction was affected in all patients. Synchronous
involvement of the cervical and thoracic spine occurred in
3 (27%%) patients. Only two (18%) patients had a cystic
component to their ependymomas. The mean length of
radiological follow-up was 6.4  2.7 years (range 3–12 years).
Tumor growth was observed in 2 (18%) patients. Symptoms
related to the intramedullary tumor were noted in one (9%) of
these patients and included small spasticity in the lower limbs
with a positive Babinski sign. Before these mild symptoms of
intramedullary tumor occurred, this patient had underwentTable 3 – Characteristics of patients harboring extramedullary 
Prognostic factor 
En
co
(22 p
Mean age at ﬁrst symptoms (years) 18.
Age (years) <18 11 
≥18 11 
Sex Female 14 
Male 8 
Tumor location Cervical 16 
Thoracic 12 
Lumbo-sacral 7 
Coexisted intramedullary tumor Yes 10 
No 12 
Coexisted intracranial meningioma Yes 16 
No 6 
Coexisted non-vestibular schwannoma Yes 9 
No 13 symptomatic meningioma surgery in the thoracic region. The
second patient has remained asymptomatic. Tumor growth
was associated with a younger age at the onset of NF2-related
symptoms. During the radiological follow-up, in two patients
new intramedullary spinal tumors were revealed. These tumors
are asymptomatic and are subject to observation.
3.3. Extramedullary spinal tumors and cauda equina
tumors
Characteristics of patients with extramedullary spinal tumors
and cauda equina tumors are listed in Table 3. 22 patients had
one or more intradural extramedullary tumors. In 6 patients
both extramedullary and cauda equina tumors were detected.
In 10 patients extramedullary spinal tumor coexisted with
intramedullary tumor. Most tumors were located in theand cauda equina tumors.
No. of patients (%) p-Value
tire
hort
atients)
Symptomatic
tumors
(6 patients)
Asymptomatic
tumors
(16 patients)
2  9.9 17.2  9.4 18.6  10.3 0.76
4 (67) 7 (44) 0.63
2 (33) 9 (56)
2 (33) 12 (75) 0.19
4 (67) 4 (25)
5 11 0.11
1 11
0 7
4 (67) 6 (38) 0.46
2 (33) 10 (62)
6 (100) 10 (62) 0.22
0 (0) 6 (38)
2 (33) 7 (44) 0.96
4 (67) 9 (56)
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affected in 6 patients. Among 22 extramedullary and cauda
equina patients 6 were symptomatic: 4 patients had motor and
sensory deﬁcits and 2 patients presented with sensory deﬁcits
without weakness in the extremities. Three symptomatic
patients presented with their symptoms on admission. In the
mean radiological follow-up period of 6.7  3.4 years (range 2–
16 years) four tumors in 4 patients demonstrated growth.
Three patients in this subgroup became symptomatic while
the other one remain asymptomatic in the follow-up. It was
found that symptomatic extramedullary spinal tumors were
associated with coexisted intracranial meningiomas and
coexisted intramedullary tumors, however, statistical analysis
showed no statistical signiﬁcance (Table 3). At the end of
follow-up three de novo tumors (radiological appearance of
meningiomas) appeared in 3 patients. These tumors, however,
did not exhibit signiﬁcant growth in control imaging studies
and are being monitored.
3.4. Surgical treatment
3.4.1. Intramedullary tumors
Two patients underwent tumor resection. Indication for
surgery was the presence of related neurological symptoms
in one patient and the conﬁrmation of a radiological progres-
sion in the second case. In the ﬁrst patient the second equally
important indication for surgery apart from mild neurological
symptoms was the need for ABI implantation because of
bilateral deafness. Complete tumor resection was achieved in
both patients. Intraoperative monitoring was performed
during these surgeries. Histological analysis revealed ependy-
momas (WHO GII) in both patients. Postoperatively, neurolog-
ical function was worse in both cases. In the symptomatic
patient partial neurological recovery was observed and despite
the patient is ambulatory she still has mild symptoms of
proximal upper extremity weakness. There is no tumor
recurrence during the 4-year postoperative follow-up. In the
second case of asymptomatic tumor rapid decline was
observed after the operation (including tetraparesis and
respiratory failure) that has been probably related to concomi-
tant foramen magnum meningioma. On the other day
meningioma was removed and the patient fully recovered.
This patient developed small recurrent tumor on subsequent
imaging studies three years after surgery. Since tumor
recurrence is asymptomatic the patient remains in observa-
tion.
3.4.2. Extramedullary tumors and cauda equina tumors
Fifteen intradural extramedullary tumors were surgically
removed in 12 patients. Histological analysis showed menin-
giomas and schwannomas in 13 and 2 cases, respectively.
Three patients were operated twice: the second surgery for
another tumor was performed 3, 9 and 15 years after the ﬁrst
spinal surgery. The clinical indications for surgery included 6
symptomatic cases, 7 large but asymptomatic tumors that
cause spinal cord compression, 1 asymptomatic moderate-
sized C1-C2 meningioma removed during expanded procedure
for vestibular schwannoma and one asymptomatic tumor that
proved radiological progression in the follow-up. In 11 patients
postoperative period was uneventful with full neurologicalrecovery. However, 1 patient showed only moderate improve-
ment and his motor deﬁcit proved permanent. Among patients
who underwent surgery the mean postoperative clinical and
radiological follow-up period was 6.0  4.2 years (range 2–14
years) and no patients developed recurrent tumors.
4. Discussion
Neuroﬁbromatosis type 2 (NF2) is a heritable tumor predispo-
sition syndrome that leads to the development of multiple
intracranial and spinal tumors. About 60% of NF2 patients had
single or multiple spinal tumors [3,4,6,12]. It is believed that in
NF2 patients spinal tumors besides meningiomas are associ-
ated with disease severity [13].
The results of the present study tend to agree in several
respects with those of previously published works on spinal
tumors in patients with NF2 [4–6,9]. In the present study over
70% of NF2 patients had spinal tumors which is comparable to
previously reported data [3,4,6,12]. Patients with spinal tumors
had a lower age at ﬁrst symptoms of the disease, higher
number of intracranial meningiomas and intracranial non-
vestibular schwannomas (p < 0.05). Among 34 patients
11 (32%) had intramedullary tumors, 22 (65%) had extrame-
dullary tumors, and 8 (24%) had tumors of the cauda equina. In
a study of Aboukais et al. [12] patients with intra-, extra-
medullary and cauda equina tumors accounted for 22.5, 45 and
31% of the entire NF2 cohort, respectively. Of their 48 patients
with spinal tumors, 20 were symptomatic (among which
prevailed extramedullary tumors) and in 17 patients the ﬁrst
symptom of the disease was related to spinal tumors. Authors
[12] emphasize that contrary to popular belief spinal tumors in
NF2 could be associated with signiﬁcant morbidity. Our
experience does not conﬁrm this opinion. In the mean
follow-up period of almost 7 years we found 7 symptomatic
cases (one intra- and six extramedullary tumors) and only 6
patients demonstrated their tumors growth. In contrast to
intramedullary tumors which are associated with less favorable
functional prognosis after surgery, extramedullary tumors give
the possibility of full recovery after surgical treatment.
Our study conﬁrms that high percentage of NF2 patients
with ependymomas reveal evidence of extramedullary spinal
tumors and intracranial meningiomas (both in 91%) which is
similar to previous reports [1,5,14]. This proves that intrame-
dullary tumors in NF2 patients are associated with disease
severity. We also found that in all patients some tumors were
located in the cervical spine which is consistent with previous
reports [14]. This predilection of ependymomas for cervical
cord and craniomedullary junction (CMJ) is different from that
for patients with sporadic tumors which are more commonly
located within the brain and less common in the cervical cord
[15,16]. Moreover, spinal ependymomas in NF2 patients are
usually multiple and present with typical appearance of a
‘‘string of pearls’’ in neuroimaging. In our study, similarly to
previous works [4–6,9], only two patients (18%) underwent
surgical treatment for their ependymomas. In our analysis it
was found that the presence of tumor-associated cysts and
young age at ﬁrst symptoms of NF2 may be associated with
tumor growth, the occurrence of clinical symptoms and the
need for surgical intervention in patients with intramedullary
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no meaningful conclusions can be drawn. Better outcome of
surgical treatment for intramedullary ependymomas has been
achieved with growing but asymptomatic tumor like in sporadic
intraspinal tumors [17]. The majority of our patients remained
asymptomatic during an extended follow-up period. This is
quite typical for NF2 patients that their ependymomas are often
asymptomatic and usually encountered during routine imaging
studies of the central nervous system. Our study corroborates
previous reports [12,14] suggesting that most NF2 patients with
ependymomas can be safely monitored without indication for
surgical treatment. It should be noted, however, that even non-
growing, asymptomatic intramedullary spinal tumor in patient
with NF2 may be an indication for surgery: we should consider
tumor removal when implantation of ABI is needed because
after this procedure we lack the possibility of any tumor growth
monitoring by MR imaging. Aboukais et al. [12] reported that in
their three symptomatic patients operated on for intramedul-
lary tumors, neurological recovery was only partial in two
patients and absent in one. In contrast no postoperative
worsening was reported for the three asymptomatic patients.
This suggests that growing tumors should be considered for
surgery before clinical symptoms appear. Therefore our
treatment strategy in all cases of spinal cord tumors assumes
strict clinical and radiological monitoring considering surgery in
any case of documented tumor growth before the onset of
neurological symptoms.
5. Conclusions
Spinal tumors in patients with NF2 are most commonly found in
the cervical spine and are associated with the disease severity.
These tumors remain asymptomatic in the long-term follow-up
and rarely require surgical treatment which is especially typical
of intramedullary tumors. It seems that close surveillance with
MR imaging is a reasonable option for asymptomatic spinal
tumors. Nevertheless, intramedullary tumor removal in non-
growing and asymptomatic cases may be an option when ABI
implantation is considered. Symptomatic tumors and those of
documented growth should be eligible for surgical intervention.
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